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Abstract  
Orodispersible films (ODFs) are a novel dosage form with strongpossess potential to 
facilitate oral drug delivery to infants and young children; however, documentation of their 
acceptability in this age group is lacking. This study is the first to explore the initial 
perceptions, acceptability and ease of use of ODFs for infants & preschool children and their 
caregivers through observed administration of the type of dosage form.  
Placebo ODFs were administered to children stratified into aged 6 to 12 months, 1 year, 2 
years, 3 years, 4 years and 5 years old aged 6 months to 5 years in a hospital setting, with 
participants stratified into 6 age groups, including aged 6 to 12 months, 1 year old, 2 years 
old, 3 years old, 4 years old and 5 years old and into those with an acute illness or long-term 
stable condition in hospital setting. Acceptability of the dosage form and end-user views were 
assessed by a) direct observation of administration b) questionnaires to caregivers and nurses 
and c) age-adapted questionnaires for children aged 3 years and over. 
The majority of children (78%) aged 3 years and over gave the ODF a positive rating both on 
verbal and non-verbal scales. Despite little prior experience, 78% of caregivers expressed 
positive opinion about ODFs before administration. After the ODFs were taken, 79% of 
infant caregivers and 86% caregivers of preschool children positively rated their child’s 
acceptance of the ODF. The intraclass correlation coefficient value was 0.92 showing good 
agreement between ratings of caregivers and nurses.  
ODFs showed a high degree of acceptability among young children and their caregivers. If 
drug loading permits, pharmaceutical companies should consider developing paediatric 
medicines in this format. The methodology described here is useful in assessing the 
acceptability of active ODF preparations and other dosage forms to children.  
 
Funding details: 
This work was funded by NIHR Research for Patient Benefit (RfPB) Programme- 
Competition 17. 
 
Disclosure statement: 
The authors have no conflicts of interest relevant to this article to disclose. 
 
Biographical note: 
Dr. Mine Orlu is a Lecturer in Pharmaceutics at UCL School of Pharmacy and an expert in 
developing geriatric medicines. 
 
Dr Yucheng Sheng is a clinical pharmacologist at GSK and an Honorary Research Associate 
at UCL. He was a Post-Doctoral Research Associate at UCL School of Pharmacy at the time 
this analysis was conducted.  
 
Dr Sejal Ranmal is the Formulation Director at Interact and has background in paediatric 
formulations development. She was a Post-Doctoral Research Associate at UCL School of 
Pharmacy at the time this analysis was conducted.  
 
Prof Catherine Tuleu is a Professor in Paediatric Pharmaceutics at the UCL School of 
Pharmacy and a leading expert in developing paediatric medicines. 
 
Dr Paul Seddon is a Paediatric Consultant at the Royal Alexandra Children's Hospital, 
Brighton and Sussex University Hospitals NHS Trust. 
 
 
Page 2 of 19
URL: http://mc.manuscriptcentral.com/udrd  Email: v.torchilin@neu.edu, Alfred.Stracher@downstate.edu
Drug Delivery
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
3 
 
Introduction 
The European Union Paediatric Regulation by the European Medicines Agency (EMA) is about to 
celebrate its 10
th
 anniversary. Its aim is to incentivise companies to generate evidence towards 
regulatory approval of medicines for managing childhood conditions. One critical parallel objective is 
the development of age-appropriate formulations dosage forms to ensure that children will have 
access to dosage forms with a positive benefit-risk balance. However, there is still a paucity of data on 
end-user requirements and acceptability of formulationstype of dosage form, which limits choice in 
the development of paediatric medicines. 
Orodispersible films (ODFs) are postage stamp sized strips of thin polymeric films formulated to 
quickly disintegrate in the mouth when placed onto the tongue (Hoffmann et al, 2011). ODFs have 
been presented as a promising formulation platformtype of dosage form for non-standard patient 
populations who experience difficulties swallowing oral medicines, such as children and older adults 
(Slavkova and Breitkreutz, 2015). An increasing number of studies have focused on their 
pharmaceutical development, including formulation optimisation, characterisation, assessment of 
mechanical properties and efficient taste masking of the drug to be loaded into the film (Hoffmann et 
al, 2011; Visser et al, 2015; Borges et al, 2015; Preis et al, 2013; Brniak et al, 2015). ODFs have been 
recently proposed as customized small scale pharmacy preparations for individualised 
pharmacotherapy (Visser et al, 2014). ODFs are an attractive solid dosage form option for 
administering medicines to young children given the problems with conventional tablets and capsules, 
including difficulty in swallowing. An Ondansetron ODF has been marketed in the UK since 2010 for 
the management of chemotherapy-induced and post-operative nausea and vomiting in children 
(medicines.org.uk, 2017). However, there are currently no published empirical studies demonstrating 
the acceptability of ODFs among children and their caregivers in acute or non-acute situations. 
Appropriate and acceptable formulations dosage forms are of vital importance in paediatric 
prescribing. Patient acceptability has been defined as “the overall ability and willingness” of the 
patient and their caregiver to administer the medicines as intended (EMA, 2013).
 
This can have a 
major effect on adherence and therefore effectiveness of treatments. The EMA requires evidence of 
the suitability of dosage forms to be included in all Paediatric Investigation Plans (PIPs) where 
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possible, and for patient acceptability to be assessed during pharmaceutical and clinical development. 
Nevertheless, methodologies for assessing acceptability are still fragmented, and more research is 
needed to contribute towards the development of a globally harmonised approach (Kozarewicz, 2014; 
van Riet-Nales et al, 2016).  
The primary aim of the STAMP (Study into Thin orodispersible film Acceptability as Medicine for 
Preschool children) study was to explore the acceptability of ODFs by infants (aged 6 months to 23 
months) and preschool children (2 to 5 years). The secondary objective was to develop a methodology 
for testing acceptability of ODFs in young children, and to explore the agreement between individuals 
rating acceptability after observing children’s behaviour and reactions to orally administered dosage 
forms. The study involved combining questionnaire responses with observed administration of the 
placebo dosage form, to obtain a validated measure of end-user acceptability.  
 
Methods 
STAMP was a single site, open label trial using placebo ODFs (commercially manufactured by Bouty 
SpA, Milano, Italy). The ODFs were 6cm2 in size (3cmx2cm), flexible, opaque white, odourless and 
slightly sweetened, with average weight of 85.0 mg/film ± 5.0%. The study participants were children 
aged 6 months to 5 years 11 months, together with their main caregivers in paediatric outpatient and 
emergency department settings at the Royal Alexandra Children's Hospital, Brighton, UK.  
Participants were stratified into 6 age groups, including n= 8 aged 6 to 12 months, n=25 aged 1 year 
old, n=33 aged 2 years old, n=20 aged 3 years old, n=11 aged 4 years old and n=13 aged 5 years old. 
Recruitment was stratified by age to ensure a spread across the age range, and approximately 
Approximately half the participants were recruited from the outpatient department and half from the 
emergency department, representing both stable and acutely ill children, respectively. Ethical 
approval was granted by the NHS National Research Ethics Service (NRES) (REC 13/LO/0134). 
The study design is illustrated in Figure 1. Pre- and post-administration questionnaires were 
developed to capture end-user perceptions of acceptability as described below:  
1. Pre-administration caregiver questionnaire: completed by the caregiver prior to administration of 
the ODF. This captured participant demographics including the child’s age, gender, and feeding 
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status (e.g. puree, soft chew food, solid food), including presence of any existing feeding problem. 
It also sought the caregivers’ knowledge, experience and initial perceptions of ODFs as a means 
of delivering medicines. 
2. Post-administration children’s questionnaire: completed by children aged 3 years and older 
following administration of one placebo ODF. This questionnaire used a five point facial hedonic 
scale anchored with statements as to whether the child liked taking the ODF, ranging from “not at 
all” to “very much”. A second question assessed the participants’ willingness to take an ODF 
again. 
3. Post-administration caregiver questionnaire: completed independently by caregivers after 
observing administration of the ODF. This included 5-items from the Medication Acceptance 
Scale (MAS) recording observed child behaviours and reactions to ODF administration (Kraus et 
al, 1999).
 
The scale measures five behavioural distress items including cry, facial expression, 
body movement/level of agitation, reaction to placement in the mouth, and swallowing of the 
medication. This questionnaire also captured any concerns, and the caregivers’ willingness to 
administer ODFs again in the future.  
4. Post-administration nurses questionnaire: completed independently by a research nurse after 
observing administration of the ODF. This questionnaire also incorporated the MAS.  
 
Acceptability of the ODF was measured based on 1) successful administration of the ODF, 2) 
responses to the five point facial hedonic scale by children aged 3 years and older, and 3) the total 
score on the 5-item MAS given by caregivers and nurses. For children aged 3 years and older, a score 
of 3 and above was regarded as `acceptable`. For the MAS scale, the same scoring system as Kraus et 
al was used: 0 to 2 points were allocated for each item resulting in a total score between 0 and 10 
(with 0 indicating the lowest level of acceptance and 10 the highest) (Kraus et al, 1999). The original 
description of MAS did not specify a threshold value for the definition of medicines acceptability 
(Kraus et al, 1999). In this study, a total score of 5 or above was regarded as acceptable. It was pre-
specified that if a child scored 0 for the individual item on swallowing (indicating spitting out the 
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entire dose or vomiting), the total MAS score of 0 was recorded without scoring the other 4 items of 
the questionnaire.  
All data were collected on paper questionnaires at the clinical site and later transcribed electronically 
using Qualtrics (Utah, USA) for data analysis by the researchers. 
 
Sample size 
The main aim of the study was to obtain descriptive data on the acceptability of ODF. There are few 
published studies in this area, and no comparison on acceptability with an existing dosage form is 
being made. A power calculation would not be suitable way of determining the number of participants 
for this study. The number of participants has therefore been determined from experience in previous 
similar studies, both from our group and from the literature. In a previous study by this group, this 
sample size provided adequate data to accurately characterize the acceptability of minitablets in a 
similar population (Thompson SA et al, 2009) 
 
Statistical Analysis 
Statistical analysis was performed using R version 3.0.2 (R Core Team, 2013).One-way intraclass 
correlation (ICC) with 95 percent confidence interval  was performed to evaluate the extent of 
agreement of the post-administration MAS score between caregivers and nurses (McGraw and Wong, 
1996). An ICC of 0.75 or above indicates good and above 0.9 excellent agreement (Sayinsu et al, 
2007).  
 
Intended space for Figure 1 
Figure 1: Flowchart for STAMP study 
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Results 
In total, 110 children were recruited in the study (59% male), of which 66 were infants and 44 were 
preschool children.The majority of participants (91%) were reported to be eating normal family food 
while 6% had reached soft chew solids and the remaining 3% were reported to be eating purees. Fifty-
seven children (52%) were recruited from the paediatric outpatients, representing those with a long-
term stable condition, and 53 from the emergency department, representing those with an acute 
illness.  
 
ODF Administration Outcomes 
The results of the swallowing of medicine section of MAS were used to assess children’s ability to 
take the ODF. 65% of caregivers and 62% of nurses reported that children swallowed the ODF 
without loss. In 15% of children, a partial loss of administered ODF was observed by caregivers and 
nurses: in these children the ODF became stuck to teeth, lips or palate resulting in it being partially 
spat out or removed by the child using their finger. No caregivers or nurses scored 0 for the individual 
swallowing item corresponding to the observation of spitting out entire dose of ODF or vomiting. One 
incident of gagging and one of vomiting was reported by caregivers but in both these instances, the 
research nurse deemed this to be due an underlying illness and not the dosage form itself.  
 
Acceptability of ODFs to children 
Overall, 40 children aged 3 years and older self-reported acceptability using the post-administration 
questionnaire. The majority of children (78%) rated the dosage form ≥ 3 on the 5-point hedonic scale, 
and 63% reported that they `very much` liked the ODF. 72% reported a willingness to take an ODF 
again.  
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Intended space for Figure 2 
Figure 2 Percentage of responses from children aged 3 years and older to a. “How much did you like 
the medicine wafer?” ranging from 0: “not at all” to 5:“very much”. b. Would you be happy to take it 
again? 
 
Acceptability of ODFs as recorded by caregivers and nurses 
Of the caregivers participating in the study, 66 had an infant child aged less than 2 years, and 79% of 
these respondents scored ≥5 on the MAS scale. The remaining 44 caregivers had a child at preschool 
age (≥2 years), and 86% scored ≥5 on the MAS scale. Over half of caregivers of pre-school children 
(52%) scored 10 on the scale indicating the highest level of acceptance. Nurses allocated a score ≥5 
on the MAS scale in 83% of infants, and 91% of pre-school children. The caregivers and research 
nurses showed excellent agreement on MAS scores with the ICC value 0.92 (95% CI: 0.886 – 0.945).   
 
 
Intended space for Figure 3 
Figure 3: Percentage of responses from a. caregivers and b. nurses reporting ODFs acceptable (≥5 on 
the Medication Acceptance Scale) and not acceptable (<5 on the Medication Acceptance Scale) for 
infants and pre-school children 
 
Acceptability of the dosage form was found to be similar between infants recruited from the 
emergency department and outpatients’ clinic according to the MAS scores. Among caregivers, 78% 
and 85% scored ≥5 on the total MAS for acute and stable conditions, respectively. Among nurses, this 
was closer at 83% and 86%, respectively.  
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Intended space for Figure 4 
Figure 4: Percentage of responses from a. caregivers and b. nurses reporting ODFs acceptable (≥5 on 
the Medication Acceptance Scale) and not acceptable (<5 on the Medication Acceptance Scale) for 
infants and children in acute and stable (chronic) settings. 
 
Perceptions of ODFs  
Prior to commencing the study, 83% of caregivers were unfamiliar with ODFs. Among respondents 
with prior knowledge, familiarity of the dosage form most commonly in the form of breath fresheners 
and snoring treatments. Nevertheless, a large majority (78%) expressed an opinion that the dosage 
form would be a good way of giving medicines to their child and 84% were not concerned about the 
use of ODFs. 98% were willing to use ODF to administer medicines to their child. The most 
frequently perceived advantages of ODFs were ease of administration and reduced risk that the 
medicine would be spat out. Some caregivers reported an assumption that younger children would 
automatically start to chew items entering their mouth, but that children ≥3 years would be better able 
to understand the use of ODF without administering water. Overall, 82% of caregivers reported that 
their child had taken a liquid medication in the past; 59% of these respondents felt that ODFs would 
be a better dosage form than administering medicine in liquid form, while 28% felt that they would be 
no different.  
After administration of the placebo sample, most caregivers preserved their opinion about ODFs. 
Overall, 79% remained not concerned and 90% remained willing to administer ODF to their child. A 
larger majority (81%) reported that the dosage form was a good way of giving medicines to their 
child. The majority of caregivers (84%) felt that the ODF size (6cm
2
) was manageable, and that the 
appearance was suitable for their child. Negative comments mentioned colour and flavour as features 
to be modified; with strawberry the most commonly suggested flavour. Caregivers also made 
suggestions regarding the shape of ODF such as child-friendly appealing shapes. Interestingly, some 
caregivers also suggested elongated shapes for the ease of administration.  
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Discussion 
This study showed a high degree of acceptability of ODFs among young children and their caregivers, 
whether assessed by caregiver questionnaire, caregiver or nurse observation, or by direct 
questionnaire to the older children. A previous study reported a high level of preference and 
adherence to filmstrips amongst healthy infants; however, this relied solely self-reported behaviour by 
parents (Rodd et al, 2011). The STAMP study is the first to assess the acceptability of ODFs using 
self-reported responses from preschool children, and using an objective measure in the form of 
observed administration of the dosage form by a research nurse.  
Amongst formulation scientists, there is awareness of inherent advantages of ODFs for special patient 
populations ranging from paediatric to bedridden and non-cooperative patients (Slavkova and 
Breitkreutz, 2015; Borges et al, 2015). This is light of the well acknowledged problems of oral liquid 
formulationsdosage forms, such as medication errors (e.g. risk of under or over dosing due to 
inappropriate dosing and risk of poor therapeutic outcome due to difficulty in using oral 
administration device) as well as the lower acceptability of parenteral and rectal drug delivery. A 
recent review article raised the possibility of using ODFs from birth (van Riet-Nales et al, 2016).  
However ODFs have been so far only used for niche clinical conditions. It is unclear why ODFs are 
not more widely used. One limitation is that a therapeutic effect must be achievable at the low doses 
that can be loaded into the polymeric film. The lack of established quality control / quality assurance 
criteria and related methodologies may be a further barrier. However, perhaps the biggest obstacle has 
been that the acceptability of ODFs to young children and their caregivers has not been explored in 
depth. The preference and perception of patients towards novel dosage forms is critical for the 
acceptability of the prescribed medicine. This translational study supports the potential of ODFs for 
broader paediatric indications and provides evidence to stimulate the interest of pharmaceutical 
industry to develop these.  
The perception of the patient and caregiver about the dosage form itself plays a crucial role in the 
optimisation of acceptability and the adherence to treatment (Matza et al, 2013). Previously our 
research group took the initiative in exploring the acceptability and suitability of placebo minitablets 
for preschool-aged children (Thompson et al, 2009). The positive outcome showing the ability of 
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majority of youngest children to swallow minitablet has paid the way for the further academic and 
industrial trials with the aim of determining the acceptability of paediatric medicines (Mistry and 
Batchelor, 2017) hence positively influence the implementation of this new dosage form into 
manufacturing and clinical settings. 
The questionnaires were adapted to the needs of the present study and improved with the involvement 
of lay members (National Institute of Health Research - Medicines for Children Research Network, 
Parent Representatives and Young Persons Advisory Group) at an early stage. This review enabled 
the format of questions to be appropriately designed for the targeted age group. In particular, 
involvement of young people improved the design of the artwork used in participant information 
leaflets which supported volunteer recruitment. It was interesting to note that particular care must be 
taken when phrasing questions to ensure they are correctly understood by child respondents. As an 
example, in the post-administration children’s questionnaire, respondents were asked “would you like 
to take it again?” with the aim to determine if the respondent would be happy to receive the ODF 
again at some point in the future. However, the nurse reported that some younger children understood 
this to mean whether they would like to receive another ODF immediately and therefore responded 
negatively, although their response about the ODF administration itself was positive. This 
demonstrates the complexity in stating questions clearly to avoid any potential misinterpretation or 
unintentional response. Another study design limitation was the restricted diversity of the sample 
population recruited from one site. The caregivers completed the questionnaires in the presence of the 
nurse, and children (over 3) completed the questionnaire in the presence of their caregiver. It is 
possible that this may have biased the responses, and this issue could be explored in future studies. 
This is an exploratory study, with sample size based on previous similar studies. A larger study would 
be needed to  with limit sample size and that a wider study would be necessary to confirm the study 
findings and to examine any differences in acceptability between the age strata. The data generated 
forms the basis for further development of this novel dosage form. 
 
Conclusions 
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This study demonstrates that ODFs are an acceptable, age-appropriate dosage form for infants and 
preschool children. The high degree of concordance between parental and nurse ratings suggest that 
this methodology is a reliable way to assess acceptability of novel dosage forms in this age group.  
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